Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: A network meta-analysis and systematic review

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 1, 2016, Pages

  Desborough, Michael ^a   Estcourt, Lise J ^a   Chaimani, Anna ^b   Doree, Carolyn ^c   Hopewell, Sally ^d   Trivella, Marialena ^d   Hadjinicolaou, Andreas V ^e   Vyas, Paresh ^c   Stanworth, Simon J ^f  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b UNIVERSITY OF IOANNINA   (Greece)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e MERTON COLLEGE   (United Kingdom)

^f NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ARTIFICIAL PLATELET SUBSTITUTE; BLOOD SUBSTITUTE; CATRIDECACOG; DESMOPRESSIN; FIBRINOGEN CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPOIETIN; UNCLASSIFIED DRUG; ARGIPRESSIN[1 DEAMINO]; BENZOIC ACID DERIVATIVE; ELTROMBOPAG; FC RECEPTOR; HEMOSTATIC AGENT; HYBRID PROTEIN; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; ROMIPLOSTIM; TRANEXAMIC ACID;

ARTICLE; BLEEDING; BONE MARROW DEPRESSION; CHRONIC DISEASE; DRUG EFFICACY; HUMAN; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); THERAPY EFFECT; THROMBOCYTE POOR PLASMA; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; BONE MARROW DISEASE; COMPLICATION; HEMORRHAGE; META ANALYSIS;

BENZOATES; BONE MARROW DISEASES; CHRONIC DISEASE; DEAMINO ARGININE VASOPRESSIN; HEMORRHAGE; HEMOSTATICS; HUMANS; HYDRAZINES; PLATELET TRANSFUSION; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; THROMBOCYTOPENIA; THROMBOPOIETIN; TRANEXAMIC ACID;

EID: 84969567669     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD012055     Document Type: Article

References (78)

1. Ades AE, Caldwell DM, Reken S, Welton NJ, Sutton AJ, Dias S. Evidence synthesis for decision making 7: a reviewer's checklist. Medical Decision Making 2013;33(5):679-91.
2. Alter PA. Diagnosis, genetics, and management of inheritied bone marrow failure syndromes. Hematology (American Society of Hematology Education Program) 2007:29-32.
3. British Committee for Standards in Haematology (BCSH). Guidelines for the use of platelet transfusions. British Journal of Haematology 2003;122(1):10-23.
4. British Committee for Standards in Haematology (BCSH). Transfusion guidelines for neonates and older children. British Journal of Haematology 2004;124(4):433-53.
5. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Research Synthesis Methods 2012;3(2):161-76.
6. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One 2013;8(10):e76654.
7. Chaimani A, Salanti G. Visualizing assumptions and results in network meta-analysis: the network graphs package. The Stata Journal 2015;15(4):905-50.
8. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration, Available from www.cochrane-handbook.org.
9. Del Giovane C, Vacchi L, Mavridis D, Filippini G, Salanti G. Network meta-analysis models to account for variability in treatment definitions: application to dose effects. Statistics in Medicine 2013;32(1):25-39.
10. Desborough M, Stanworth S. Plasma transfusion for bedside, radiologically guided, and operating room invasive procedures. Transfusion 2012;52(Suppl 1):20S-9S.
11. Dinmohamed AG, Visser O, Van Norden Y, Huijgens PC, Sonneveld P, Van de Loosdrecht AA, et al. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. European Journal of Cancer 2014;50(5):1004-12.
12. Dokal I, Vulliamy T. Inherited aplastic anaemias/bone marrow failure syndromes. Blood Reviews 2008;22(3):141-53.
13. Estcourt LJ, Stanworth SJ, MurphyMF . Platelet transfusions for patients with haematological malignancies: who needs them?. British Journal of Haematology 2011;154(4):425-40.
14. Estcourt LJ, Gregg R, Stanworth S, Doree C, Trivella M, Murphy MF, et al. Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD010982]
15. Foucar K, Langdon RM, Armitage JO, Olson DB, Carroll TJ Jr. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer 1985;56(3):553-61.
16. Franchini M, Lippi G. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfusion 2012;10(1):23-7.
17. Gordon MS, Nemunaitis J, Hoffman R, Paquette RL, Rosenfeld C, Manfreda S, et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995;85(11):3066-76.
18. Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leukemia Research 1999;23(10):953-9.
19. Heimpel H. Epidemiology and aetiology of aplastic anaemia. In: Schrezenmeier H, Bacigalupo A editor(s). Aplastic Anaemia: Pathophysiology and Treatment. Cambridge, UK: Cambridge University Press, 2000:97-116.
20. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
21. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
22. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
23. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Research Synthesis Methods 2012;3(2):98-110.
24. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Annals of Internal Medicine 2015;162(11):777-7.
25. Issaragrisil S, Kaufman D, Anderson T, Chansung K, Leaverton P, Shapiro S, et al. the Aplastic Anaemia Study Group. The epidemiology of aplastic anaemia in Thailand. Blood 2006;107(4):1299-307.
26. Jackson D, Barrett JK, Rice S, White IR, Higgins JP. A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. Statistics in Medicine 2014;33(21):3639-54.
27. Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Medicine 2013;11:159.
28. Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007;109(9):1705-14.
29. Karkouti K, Von Heymann C, Jespersen CM, Korte W, Levy JH, Ranucci M, et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery 2013;164(4):927-39.
30. Konstantopoulos K, Lauren L, Hast R, Reizenstein P. Survival, hospitalization and cause of death in 99 patients with the myelodysplastic syndrome. Anticancer Research 1989;9(4):893-6.
31. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. Journal of Clinical Oncology 2001;19(21):4165-72.
32. Kuter DJ. Milestones in understanding platelet production: a historical overview. British Journal of Haematology 2014;165(2):248-58.
33. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook forSystematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration..
34. Lidbeck J. Studies on hemopoietic dysplasia (the preleukemic syndrome). Clinical course and prognostic factors in 42 patients with dysplastic bone marrow. Acta Medica Scandinavica 1980;208(6):459-62.
35. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007;109(8):1536-42.
36. Ma X. Epidemiology of myelodysplastic syndromes. The American Journal of Medicine 2012;125(7 Suppl):S2-5.
37. Mannucci PM, Vicente V, Alberca I, Sacchi E, Longo G, Harris AS, et al. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Thrombosis and Haemostasis 1987;58(4):1037-9.
38. Mavridis D, White IR, Higgins JP, Cipriani A, Salanti G. Allowing for uncertainty due to missing continuous outcome data in pairwise and network meta-analysis. Statistics in Medicine 2014;34(5):721-41.
39. Montané E, Ibañez L, Vidal X, Ballarin E, Pig R, Garcia N, et al. the Catalan Group for the Study of Agranulocytosis and Aplastic Anemia. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica 2008;93(4):518-23.
40. Muir KR, Chilvers CED, Harriss C, Coulson L, Grainge M, Darbyshire P, et al. The role of occupational and environmental exposures in the aetiology of acquired severe aplastic anaemia: a case control investigation. British Journal of Haematology 2003;123(5):906-14.
41. National Blood Authority. Module 3 - Medical. The National Blood Authoritys Patient Blood Management Guideline. Canberra: National Blood Authority, 2012.
42. Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R, et al. Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry. Leukemia Research 2011;35(12):1591-6.
43. NICE . Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. National Institute of Health and Care Excellence 2011:TA221.
44. NICE . Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205). National Institute of Health and Care Excellence 2013:TA293.
45. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
46. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology 2015;61(10):991-6.
47. Rauff B, Idrees M, Shah SA, Butt S, Butt AM, Ali L, et al. Hepatitis associated aplastic anemia: a review. Virology Journal 2011;8:87.
48. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
49. Rhodes KM, Turner RM, Higgins JP. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. Journal of Clinical Epidemiology 2015;68(1):52-60.
50. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342:d549.
51. Roberts DJ, Prowse CV. Blood substitutes. In: Murphy MF, Pamphilon DH, Heddle NM editor(s). Practical Transfusion Medicine. 4th Edition. Chichester, UK: Wiley-Blackwell, 2013:399-409.
52. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circulation Research 2007;100(12):1673-85.
53. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analyses: an overview and tutorial. Journal of Clinical Epidemiology 2011;64(2):163-71.
54. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods 2012;3(2):80-97.
55. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS One 2014;9(7):e99682.
56. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, et al. Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology 2001;19(5):1519-38.
57. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH (editors). Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
58. Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD005011.pub4]
59. Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology (American Society of Hematology Education Program) 2007:172-8.
60. StataCorp. Stata Statistical Software. Release 12.. College Station, TX: StataCorp, 2012.
61. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.
62. Svensson PJ, Bergqvist PBF, Juul KV, Berntorp E. Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. Blood Reviews 2014;28(3):95-102.
63. Swift M. Fanconi's anaemia in the genetics of neoplasia. Nature 1971;230(5293):370-3.
64. Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. American Journal of Hematology 2013;88(2):141-50.
65. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
66. Tinmouth AT. Chapter 18: Platelet transfusion, alloimmunization and management of platelet refractoriness. Canadian Blood Services. 4th Edition. Canadian Blood Services, 2007.
67. Titmarsh GJ, Duncombe AS, McMullin MF, O'Rorke M, Mesa R, De Vocht F, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. American Journal of Hematology 2014;89(6):581-7.
68. Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, et al. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Annals of Oncology 2005;16(1):139-45.
69. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. International Journal of Epidemiology 2012;41(3):818-27.
70. Verma A, Agarwal P. Platelet utilization in the developing world: strategies to optimize platelet transfusion practices. Transfusion and Apheresis Science 2009;41(2):145-9.
71. Wardrop D, Estcourt L, Doree C, Hopewell S, Stanworth S, Murphy MF. Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD009733.pub2]
72. White IR, Higgins JP, Wood AM. Allowing for uncertainty due to missing data in meta-analysis-part 1: two-stage methods. Statistics in Medicine 2008;27(5):711-27.
73. White I. Multivariate meta-analysis: updates to mvmeta. The Stata Journal 2011;11(2):255-70.
74. White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Research Synthesis Methods 2012;3(2):111-25.
75. White I. Network meta-analysis. Stata Journal 2015;15(4):951-985.
76. Wikkelsø A, Lunde J, Johansen M, Stensballe J, Wetterslev J, Møller AM, et al. Fibrinogen concentrate in bleeding patients. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD008864.pub2]
77. Young NS, Kaufman DW. The epidemiology of acquired aplastic anemia. Haematologica 2008;93(4):489-92.
78. Zeng Y, Duan X, Xu J, Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD008235.pub2]